tirzepatide surmount 2 for the Maintenance of Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT‐MAINTAIN - Horn - 2025 - Obesity tirzepatide maximum weight loss surmount

Lang, Calvin A., Betty Jane Mills, Helen L Lang, Marica C Liu, Wayne M

Survodutide is another dual agonist targeting GLP-1 and glucagon receptors (without GIP), currently in Phase 3 trials

To stack safely requires medical oversight

Comparative data suggests tirzepatide headache rates align closely with other GLP-1 receptor agonists

GLP-1 Medications Force Food Industry Rethink Few innovations have disrupted consumer behavior as quickly as GLP-1 weight-loss medications

Whether you're considering stopping due to side effects, cost concerns, or because you've reached your health goals, understanding what happens during this period can help you maintain your progress and prepare for the changes ahead